SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as the community debates its long-term viability and tokenomics amid a broader discussion on the future of the Inter-Blockchain Communication (IBC) protocol. Investors are actively sharing polarized perspectives, with some highlighting the potential of the Cosmos ecosystem's interoperability and staking rewards, while others express frustration over recent price performance and skepticism regarding its competitive position against other layer-1 networks.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating significant buzz among traders due to its notably low circulating supply, which community members argue positions the token for potential rapid appreciation if volume picks up. Supporters are highlighting its presence in the NFT and DeFi sectors as a core value proposition, while others express skepticism, warning of the risks inherent in low-cap assets.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing attention as community members anticipate a potential Coinbase listing and potential partnerships following the completion of its token unlocks. Investors are actively discussing the protocol's real-time payroll utility and deflationary mechanics, with many maintaining a bullish outlook for its long-term adoption despite short-term price fluctuations.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and aggressive debate among traders as it reacts to shifting Bitcoin price action and broader market uncertainty. Community sentiment is deeply polarized, with bulls focusing on institutional adoption and accumulation potential, while bears highlight risks surrounding dilution, debt, and the company's heavy reliance on crypto market cycles.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is trending as investors weigh its upcoming earnings against concerns over slowing growth and competition in the cybersecurity sector. While some market participants express frustration over recent price volatility and bearish sentiment, others are closely tracking analyst sentiment regarding AI-driven identity security and potential long-term opportunities.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid intense community debate over institutional integration rumors, specifically concerning SWIFT connectivity and the potential for regulatory clarity, while sentiment remains deeply polarized between retail holders anticipating utility-driven gains and skeptics dismissing the token as stagnant or manipulative.

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Surrozen Inc

Surrozen is actively trending as investors monitor potential buyout interest and upcoming pipeline milestones involving its Wnt-modulating ophthalmology assets, with the community closely tracking coordinated institutional buying from The Column Group. Retail sentiment remains focused on the company's potential to capitalize on the high-demand Wnt pathway sector, despite ongoing discussions regarding institutional share accumulation and the strategic rationale behind its recent capital raising and lease restructuring.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

The KraneShares CSI China Internet ETF is drawing significant investor interest as market sentiment shifts toward undervalued Chinese tech giants, fueled by institutional accumulation and the unveiling of major AI breakthroughs from companies like Alibaba. Community discussion is heavily focused on potential stimulus measures and a technical breakout, with many traders emphasizing that long-term accumulation is finally translating into positive momentum despite ongoing geopolitical noise.

Volkswagen AG engages in the business of developing vehicles and components for the brands of the group. It operates through the following segments: Passenger Cars and Light Commercial Vehicles; Commercial Vehicles; Power Engineering; and Financial Services. The Passenger Cars and Light Commercial Vehicles segment includes developing vehicles, engines, and vehicle software; producing and selling passenger cars and light commercial vehicles; and the corresponding genuine parts business. The Commercial Vehicles segment focuses on trucks, buses, corresponding genuine parts business, and related services. The Power Engineering segment is involved in large-bore diesel engines, turbomachinery, and propulsion components business. The Financial Services segment provides dealer and customer financing, leasing, banking, insurance, and fleet management services. The company was founded on May 28, 1937 and is headquartered in Wolfsburg, Germany.

Volkswagen AG - ADR

Volkswagen is trending as investors and the community closely monitor its massive $5.8 billion joint venture with Rivian, intended to revitalize software capabilities and electrical architecture. Meanwhile, broader sentiment remains cautious due to significant cost-cutting measures, potential plant closures in Germany, and intensifying competition from domestic Chinese EV manufacturers.

Peabody Energy Corp. engages in the business of coal mining. It operates through the following business segments: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal, and Corporate and Other. The Seaborne Thermal segment consist of mines in New South Wales, Australia. The Seaborne Metallurgical segment includes mines in Queensland, Australia, one in New South Wales, Australia and one in Alabama, USA. The Powder River Basin segment focuses on mines in Wyoming. The Other U.S. Thermal segment reflects on the mining, preparation and sale of thermal coal, sold primarily to electric utilities in the U.S. under long-term contracts, with a relatively small portion sold as international exports as conditions warrant. The Corporate and Other segment involves administrative expenses, results from equity method investments, trading and brokerage activities, minimum charges on certain transportation-related contracts, the closure of inactive mining sites, the impact of foreign currency remeasurement and certain commercial matters. The company was founded by Francis S. Peabody in 1883 and is headquartered in St. Louis, MO.

Peabody Energy Corp. - Ordinary Shares New

Peabody Energy (BTU) is currently in the spotlight as investors debate the impact of potential policy shifts on coal demand and the company's valuation relative to its industry peers. While the stock has seen active options movement and community discussion regarding undervalued metrics, traders remain cautious of short-term volatility and production outlooks for its metallurgical and thermal coal operations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca Pharma India bolsters oncology and market access leadership

AstraZeneca Pharma India Limited ( ($IN:ASTRAZEN) ) has shared an update. AstraZeneca Pharma India Limited has strengthened its leadership team by ...

AstraZeneca Pharma India wins CDSCO approval for durvalumab

UK pharma major AstraZeneca’s majority owned Indian subsidiary, today announced that Central Drugs Standard Control Organization (CDSCO) has approved an additional indication for durvalumab solution for infusion (120mg/2.4 mL and 500mg/10 mL), for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), who have not received prior systemic therapy in India.

AstraZeneca Pharma India receives CDSCO approval for Durvalumab for patients with uHCC

AstraZeneca Pharma India, a global, science-led biopharmaceutical company, announced that Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Durvalumab solution for infusion (120 mg/2.4 mL and […] The post AstraZeneca Pharma India receives CDSCO approval for Durvalumab for patients with uHCC appeared first on Express Pharma .

Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In Treatment

AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer... ......

AstraZeneca India wins CDSCO approval for Durvalumab in cancer

New Delhi, Feb 10 : AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to sell and distribute Durvalumab solution for infusion used in cancer treatment for an additional indication. In its latest stock exchange filing, the drug company said that through this approval, “Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)”. According to the filing, “This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Brand Name: Imfinzi) for an additional indication,” said AstraZeneca Pharma India Ltd.

AstraZeneca Pharma India Ltd. is engaged in the manufacturing, distribution, and marketing of pharmaceutical products and clinical trial services. It focuses in the areas of cardiovascular and metabolic disease, cancer and respiratory, inflammatory, and autoimmune disease. The company was founded on July 11, 1979 and is headquartered in Bangalore, India.

Current Price	7,810.00
Prev Close	7,852.50
Open	7,790.00
Dividend Yield	0.37%
50-Day Moving Average	8,564.46
Beta	-0.01
Avg. Volume	9,180.89
PE Ratio	97.41

52-Week High	10,691.00
52-Week Low	7,201.15
Market Capitalization	195.44B
EPS (Annual)	46.30
Price to Book	24.49
Revenue Per Employee	21.4M

ASTRAZEN.NSE
AstraZeneca Pharma India Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest ASTRAZEN.NSE News

ASTRAZEN.NSEAstraZeneca Pharma India Ltd.